Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT01274026 |
| Other study ID # |
183590-1 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 2011 |
| Est. completion date |
December 2013 |
Study information
| Verified date |
August 2023 |
| Source |
Tulane University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This observational study seeks to establish evidence:
1. that physiologic changes, unrelated to effect on the Phenylalanine Hydroxylase (PAH)
enzyme, occur in Phenylketonuria (PKU) patients who are treated with sapropterin
(Kuvan®) therapy,
2. that these changes may be caused by enhanced neurotransmitter synthesis in the brain or
an upregulation of gene expression (increasing the ability of genes to produce
functional enzymes),
3. and that beneficial changes in behavior and cognition, especially executive functioning
skills may result.
The objective of this study is to correlate any change in behavior and executive function
skills of PKU patients who are non-responsive to sapropterin effect on the PAH enzyme, as
defined by lowered blood PHE levels, with urine neurotransmitter levels and broad gene
expression prior to and after sapropterin administration.
Expected outcomes would include evidence of sapropterin effects on upregulation of enzymes
other than PAH that control neurotransmitter synthesis, and any resulting correlation with
behavioral and cognitive changes.
The investigators hope this study will inform further detailed investigations into the
biochemical and molecular actions of sapropterin (Kuvan®) that lead to increased
understanding of possible treatment effects beyond a lowered blood PHE response.
Description:
The anticipated study participant population was approximately 30 established PKU patients
receiving care from Hayward Genetics Center, who were found previously to exhibit no decrease
in blood phenylalanine (PHE) levels (nonresponders) with administration of sapropterin.
Subjects acted as their own controls. An additional number of patients naive to sapropterin
were subsequently added to the study, and the age exclusion of over 21 years of age was
omitted per IRB approval. Primary endpoints were designed to be measurement of behavioral and
cognitive function, neurotransmitter levels, and gene expression of enzyme activity after 4
weeks on treatment compared to baseline levels.
At study baseline each patient attended an approximately 1 hour clinic visit at their usual
genetics clinic location. Study purpose, design, and requirements were discussed, and
consents/assents reviewed and signed.
Rating inventories of executive function performance and behavior (BASC-2 and BRIEF tools)
were administered to patients and parents by the Principal Investigator (PI) and/or the Study
Coordinator.
Urine samples were collected non-invasively for measurement of neurotransmitter levels. Blood
as collected by venipuncture (3-5 ml) for microarray expression analysis and analysis of
plasma amino acids. 3-day food records previously provided to participants for completion
were collected.
Participants were provided with a 4 week supply of Kuvan® and instructions on how to take the
medication during the study period. The importance of maintaining usual dietary intake (food
choices and metabolic formula) to minimize any research effect not attributable to
sapropterin administration was emphasized. Sapropterin was discontinued at the end of the 4
week study period. The exception to this was for the naive patients who were found to be
responsive to sapropterin.
All of these measures were repeated at the same sites with study participants at the end of
week 4 of the study period.
At the ends of weeks 1 and 2 additional blood samples were sent to Hayward Genetics Center
for measurement of PHE and tyrosine (TYR) levels to ascertain no significant changes have
occurred in a patient's usual dietary intake. These samples were drawn at each patient's
local state health unit, as is done for usual monitoring. Nutrient analysis of the 3-day food
diaries was conducted at Hayward Genetics Center.
1. Behavior and executive function were assessed using published validated inventories,
completed as patient self-reports and as parent (or guardian) reports when appropriate.
Instruments used were the Behavioral Assessment System for Children (BASC-2) parental
Rating Scale and Self-Reporting Personality Rating Scale, and the Behavioral Rating
Inventory of Executive Function (BRIEF) Parent Form Instruments of Executive Function.
Completed inventories were scored using electronic evaluation instruments by the Study
Coordinator and PI, with consultation from Harvard Medical Center experts as needed.
2. Urine samples were non-invasively collected and sent for analysis of catechols and
neurotransmitters to an NIH laboratory specializing in this technique. Samples were
blinded to this laboratory to prevent bias.
3. Microarray analysis of blood samples was conducted at Hayward Genetics Molecular
Laboratory to determine any effect on gene expression, and thus enzyme activity, as a
result of sapropterin administration.
4. Plasma amino acids were analyzed at Hayward Genetics Biochemical Laboratory to document
that patients are "nonresponsive" to sapropterin (no resultant lowering of blood PHE);
and to monitor any changes in plasma amino acids that could indicate a patient's failure
to maintain usual dietary restrictions. Patients naive to Kuvan who responded were noted
and function as comparators.
5. 3-day food diaries completed by patients (or parent/guardians) at home documented any
substantive changes in usual dietary intake during the study period. These were analyzed
at Hayward Genetics Center using the MetabolicPro web-based analysis program.
